Neurology

Patients taking either of the 2 anticoagulants showed no large differences on 4 cognitive test scores at 2 years, according to authors of the GIRAF trial.

In the first review of its kind, authors found encouraging evidence supporting the use of hypnosis for chronic neuropathic pain treatment. Find key results in our new slideshow.

AHA 2021: E-cigarette users were found to have a 15% higher risk of a cerebrovascular accident at a younger age than those who smoked combustible tobacco cigarettes.

When addressing mental health with patients with obesity, a thoughtful approach that balances psychological health and weight loss is critical, explains Dr Ethan Lazarus.

The daily oral CGRP inhibitor is the only agent in the class developed specifically for prevention vs acute treatment of episodic migraine.

What state has the lowest suicide rate? Which one has the highest share of adult depression? Find the answers and more insights from a nationwide analysis, here.

The DHE nasal spray delivered pain relief at 2 hours for 66% of patients; 93% of those remained pain-free at 24 hours and 86% at 2 days post-dose.

Substituting regular salt with low-sodium alternative was found to reduce the risk of stroke, major cardiovascular events, and death in a new study presented at ESC Congress 2021.

Oral CGRP inhibitor atogepant significantly reduced monthly headache days and improved daily function in adults with 4 to 14 headaches per month.

A new study suggests that walking even 3 or 4 hours a week may reduce long-term mortality from any cause in patients with a history of stroke.

Compared to psychiatrists and subspecialists, the proportion of visits to primary care was higher for patients with depression or anxiety and any mental illness in a new cross-sectional study.

In a new scientific statement, the AHA/ASA recommends that the first poststroke visit should occur earlier in primary care. Details plus 5 more key points primary care physicians should know.

A new analysis of the large ASPREE trial found statin use in older adults is not associated in the incidence of dementia or a decline in neurocognitive health.

The FDA approved today the first drug that targets the pathophysiolgic process responsible for Alzheimer disease and the first drug since 2003 to be approved for any Alzheimer treatment.

Adults with OCD were more than 3 times as likely to have an ischemic stroke after age 40 than those without the disorder, according to a study published in Stroke.

Reports of a rare, severe type of blood clot in 6 women in the US led the agencies to halt use of the J&J product, out of an abundance of caution.

Brain fog topped the list of neurological symptoms in patients with long-haul COVID-19 whose illness was not severe enough to warrant hospitalization, according to a novel study.

Headache specialist Peter McAllister, MD, discusses how the new migraine medications differ from existing therapies.

Preliminary findings being presented at the International Stroke Conference 2021 show some of the same risk factors associated with stroke in older adults also cause stroke in younger adults.

International Stroke Conference 2021: A new analysis of the landmark REDUCE-IT trial found that adding icosapent ethyl to treatment regimens that already include statins further reduces stroke risk.

Study: Anosmia, myalgias, and headache were the most common extrapulmonary symptoms seen in COVID-19 patients at first presentation, say investigators.

International Stroke Conference: Adults with dementia are more likely to be infected with COVID-19, but no more likely to die from it vs those without cognitive impairment.

Stroke patients are nearly 50% more likely vs heart attack patients to develop depression, according to new research being presented at the upcoming International Stroke Conference.

Gradually worsening weakness in the shoulders, neck, and face of 4-5 days' duration is the presenting complaint of a man in his 60s. ED physician Brady Pregerson, MD, asks, "What's your diagnosis?"

New and highly specific migraine drugs have significantly changed the clinical landscape for patients. We talked with Peter McAllister, MD, about where the research goes next.

A recent survey queried cluster headache patients to compare cluster headache pain intensity to other painful disorders. The results, highlighted in this quick slideshow, may surprise.

Antidepressants, although guideline-recommended and widely prescribed for common pain conditions, may not be as effective as perceived. Author of a new meta-analysis explains.

Acupuncture, massage, meditation—what does the latest research say about these and other popular alternative therapies for pain management?

Migraine headaches are a condition commonly seen in primary care. Here is a top-line look at the evidence for efficacy of the wide range of treatments available.

In a phase 2/3 study, nearly half of rimegepant-treated patients demonstrated ≥50% reduction in the number of moderate-to-severe migraine days per month